Triple-Marker Prenatal Screening Program for Chromosomal Defects

Kazerouni, N. Neely; Currier, Bob; Lorey, Fred; Roberson, Marie

doi:10.1097/01.aog.0b013e3181ba09e6

Cited by 18 publications

(23 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All sources are mandated by California law to report diagnosed chromosomal abnormalities (whether diagnosed by karyotype or microarray) to the program. [20][21][22][23][24] Information on CCHDs was collected by the linkage of screening records with all hospital discharge records through 1 year of age for each study infant (wherein records were linked with the use of multiple identifiers [baby and mother date of birth; baby first and last name; mother first, last, and maiden name, address, phone number, and hospital of baby birth]). These records include all inpatient discharge information that is submitted to the state each time a patient is treated in a licensed general acute care hospital in California and includes all diagnoses present at the time of discharge based on 4-or 5-digit codes from the Ninth Revision of the International Classification of Diseases.…”

Section: Methodsmentioning

confidence: 99%

Risk of critical congenital heart defects by nuchal translucency norms

Jelliffe‐Pawlowski

Norton

Shaw

et al. 2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Risk of critical congenital heart defects by nuchal translucency norms

Jelliffe‐Pawlowski

Norton

Shaw

et al. 2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

“…Followup diagnostic services of genetic counseling, ultrasound and amniocentesis are offered at state-approved Prenatal Diagnosis Centers (PDCs) and the costs of these services are covered by the Expanded AFP Program. Details about the California Prenatal Screening Program and its operation were covered in previous publications (Cunningham et al, 1999;Kazerouni et al, 2009).…”

Section: Methodsmentioning

confidence: 99%

“…In March 2009, a first-trimester screening component was added to the State's Program. The primary focus of Prenatal Maternal Serum Screening Programs has been the detection of Down syndrome, trisomy 18, Smith-Lemli-Opitz syndrome (SLOS), open neural tube defects (NTDs), and abdominal wall defects (AWD) (Kazerouni et al, 2009). Because the California Prenatal Screening Program includes follow-up diagnostic services, the program has been aware that many other structural abnormalities are detected in the screen-positive population.…”

Section: Introductionmentioning

confidence: 99%

Ancillary benefits of prenatal maternal serum screening achieved in the California program

et al. 2010

Self Cite

View full text Add to dashboard Cite

Objective To evaluate the extent of fetal structural abnormalities, other than neural tube and abdominal wall defects (AWDs), identified by California's Prenatal Screening Program. MethodsThe Quad Marker Prenatal Screening records of 516,172 women were examined for screening interpretation and the diagnosis of structural abnormalities detected via follow-up. Women who were screenpositive for trisomy 21, trisomy 18, neural tube defects (NTDs) or Smith-Lemli-Opitz syndrome (SLOS) received follow-up services at state-approved Prenatal Diagnosis Centers (PDCs). Detailed reports of services and diagnostic information were linked in a database to the original screening results.Results A total of 26 323 women received follow-up ultrasound services at the PDCs in the study time period. Of these women, 1085 (4.1%) were identified as having fetuses with significant structural abnormalities, other than NTDs (n = 207) or AWDs (n = 254). In addition to the structural abnormalities, 225 cases of fetal demise, 4 molar pregnancies, 15 cases of twin-to-twin transfusion, and 92 cases with placental abnormalities were identified. ConclusionWhile Prenatal Screening Programs do not explicitly screen for structural abnormalities other than NTDs and AWDs, clearly many other structural abnormalities may be associated with a screen-positive status. Thus, the detection of these additional structural defects can be considered an ancillary program benefit.

show abstract

“…All women in prenatal care by the 140th day of gestation have, by law, the opportunity to participate in California's Genetic Disease Screening Program (GDSP) (Dietz et al, 2007;Pearl et al, 2007). The program assesses the risk of chromosomal abnormalities using several blood analytes, including maternal serum hCG, in an annual average of 350,000 gestations (Cunningham and Tompkinison, 1999;Kazerouni et al, 2009).…”

Section: Test Datamentioning

confidence: 99%

Hormonal evidence of selection in utero revisited

Catalano

Currier

Steinsaltz

2014

American J Hum Biol

View full text Add to dashboard Cite

Objectives: Human conception cohorts in gestation during stressful times reportedly yield lower ratios of male to female live births than do other conception cohorts. Much literature attributes this phenomenon to spontaneous abortion of less fit male fetuses. Controversy remains, however, as to whether stressful times make males fetuses less fit ("Shifting Distribution" of fitness) or whether male fetuses need greater fitness to avoid spontaneous abortion during stressful times ("Shifting Criterion" for survival).Methods: Although research using gestational hCG as a signal of fetal fitness reports support for the latter mechanism, we believe an analytic error casts doubt on those findings. Here we offered an alternative test that corrects the error.Conclusion: This more accurate test found similar results to those originally reported. Am. J. Hum. Biol. 27:426-431, 2015.

show abstract

Triple-Marker Prenatal Screening Program for Chromosomal Defects

Cited by 18 publications

References 1 publication

Risk of critical congenital heart defects by nuchal translucency norms

Risk of critical congenital heart defects by nuchal translucency norms

Ancillary benefits of prenatal maternal serum screening achieved in the California program

Hormonal evidence of selection in utero revisited

Contact Info

Product

Resources

About